Aspen Pharmacare Holdings Ltd (LDZA) Stock Price & News

Aspen Pharmacare Holdings Limited is a multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange in 1998, and purchased South African Druggists in 1999 before expanding into international markets. The largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016, Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for five years in the European Union. Wikipedia

About Aspen Pharmacare Holdings Ltd

CEOStephen Saad

Employees9.34K

Founded1850

HeadquartersDurban, KwaZulu-Natal, South Africa

SectorPharmaceutical industry

Websiteaspenpharma.com

All values in ZAR	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Revenue	10.70B	10.70B	8.54B	8.54B
Cost of goods sold	6.40B	6.40B	4.81B	4.81B
Cost of revenue	6.40B	6.40B	4.81B	4.81B
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	2.79B	2.79B	2.17B	2.17B
Operating expense	2.75B	2.75B	2.82B	2.82B
Total operating expenses	9.15B	9.15B	7.63B	7.63B
Operating income	1.55B	1.55B	910.00M	910.00M
Other non operating income	-150.00M	-150.00M	-9.50M	-9.50M
EBT including unusual items	-1.65B	-1.65B	577.50M	577.50M
EBT excluding unusual items	1.12B	1.12B	577.50M	577.50M
Income tax expense	81.50M	81.50M	144.50M	144.50M
Effective tax rate	-4.93%	-4.93%	25.02%	25.02%
Other operating expenses	-39.50M	-39.50M	643.50M	643.50M
Net income	-1.74B	-1.74B	736.00M	736.00M
Net profit margin	-16.22%	-16.22%	8.62%	8.62%
Earnings per share	-	-	-	-
Interest and investment income	93.00M	93.00M	83.50M	83.50M
Interest expense	-445.50M	-445.50M	-426.50M	-426.50M
Net interest expenses	-352.50M	-352.50M	-343.00M	-343.00M
Depreciation and amortization charges	-	-	-	-
EBITDA	1.79B	1.79B	1.39B	1.39B
Gain or loss from assets sale	11.00M	11.00M	-	-

Finance

Ask anything